Biodexa Pharmaceticals
Price & Volume
Stats
See more52W Range | $1.14-$73.99 |
Market Cap | $3.6M |
Shares Short | 68,470 |
Financials
See moreRevenue (12 Mos) | $83,000 |
Revenue Growth (YoY) | -64.1% |
Gross Profit (12 Mos) | -$5.4M |
Diluted EPS | -$13.23 |
News
See moreYahoo Finance • 9 days ago
Preliminary Results for the Year Ended 31 December 2024
Yahoo Finance • last month
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Yahoo Finance • last month
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Yahoo Finance • 2 months ago
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
About
CEO | Mr. Stephen Anthony Stamp |
CFO | Mr. Stephen Anthony Stamp |
Address | 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
